Bayer/GSK Levitra Has 16% Share Of New Scripts; 2003 Sales Reach $180 Mil.
Executive Summary
Bayer/GlaxoSmithKline's Levitra has a 16% share of new prescriptions in the erectile dysfunction disorder market, Bayer CFO Klaus Kuhn reported during a year-end investor meeting March 18